结直肠癌中的分子改变与生物标志物
Molecular alterations and biomarkers in colorectal cancer.
作者信息
Grady William M, Pritchard Colin C
机构信息
1Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, Washington, USA.
出版信息
Toxicol Pathol. 2014 Jan;42(1):124-39. doi: 10.1177/0192623313505155. Epub 2013 Oct 31.
Abstract
The promise of precision medicine is now a clinical reality. Advances in our understanding of the molecular genetics of colorectal cancer (CRC) are leading to the development of a variety of biomarkers that are being used as early detection markers, prognostic markers, and markers for predicting treatment responses. This is no more evident than in the recent advances in testing CRCs for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, we update a prior review published in 2010 and describe our current understanding of the molecular pathogenesis of CRC and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers), and the prediction of treatment responses (predictive markers).
摘要
精准医学的前景如今已成为临床现实。我们对结直肠癌（CRC）分子遗传学认识的进展，正促使多种生物标志物得以开发，这些标志物被用作早期检测标志物、预后标志物以及预测治疗反应的标志物。这在近期检测CRC特定分子改变以指导使用针对表皮生长因子受体的单克隆抗体疗法西妥昔单抗和帕尼单抗进行治疗的进展中体现得最为明显。在本综述中，我们更新了2010年发表的一篇先前综述，并阐述了我们目前对CRC分子发病机制的理解，以及这些改变如何与用于早期检测和风险分层的新兴生物标志物（诊断标志物）、预后（预后标志物）和治疗反应预测（预测标志物）相关联。
相似文献
1
Molecular alterations and biomarkers in colorectal cancer.结直肠癌中的分子改变与生物标志物
Toxicol Pathol. 2014 Jan;42(1):124-39. doi: 10.1177/0192623313505155. Epub 2013 Oct 31.
2
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?EGAPP 工作组的建议：在转移性结直肠癌患者中检测 EGFR 通路下游效应基因的突变，能否通过指导抗 EGFR 治疗决策来改善健康结局？
Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.
3
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
4
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.通过多基因测序预测结直肠癌患者对基于抗表皮生长因子受体（EGFR）抗体疗法的反应
BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.
5
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.循环肿瘤细胞作为接受西妥昔单抗或帕尼单抗治疗的晚期化疗难治性、RAS-BRAF野生型结直肠癌患者的纵向生物标志物。
Int J Cancer. 2015 Sep 15;137(6):1467-74. doi: 10.1002/ijc.29493. Epub 2015 Mar 4.
6
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.结直肠癌患者对抗 EGFR 药物疗效的分子预测因子。
Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. doi: 10.2174/156800910790980205.
7
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.在暴露于表皮生长因子受体（EGFR）单克隆抗体之前，KRAS野生型结直肠癌中从未检测到S492R表皮生长因子受体胞外域突变。
Cancer Biol Ther. 2013 Dec;14(12):1143-6. doi: 10.4161/cbt.26340. Epub 2013 Sep 23.
8
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?结直肠癌的预后与预测性分子生物标志物：抗 EGFR 治疗是否需要 KRAS 和 BRAF 野生型状态？
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9.
9
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.KRAS、BRAF 和 PIK3CA 突变作为西妥昔单抗疗效预测标志物在伊立替康和奥沙利铂耐药的日本转移性结直肠癌患者中的临床意义。
Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26.
10
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.表皮生长因子受体（EGFR）[更正]致癌途径的综合分子剖析，以预测转移性结直肠癌对 EGFR 靶向单克隆抗体的反应。
Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11.
引用本文的文献
1
Red meat intake interacts with a TGF-β-pathway-based polygenic risk score to impact colorectal cancer risk: Application of a novel approach for polygenic risk score construction.红肉摄入量与基于转化生长因子-β通路的多基因风险评分相互作用，影响结直肠癌风险：一种构建多基因风险评分新方法的应用
medRxiv. 2025 Jun 16:2025.06.13.25329599. doi: 10.1101/2025.06.13.25329599.
2
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.从隐窝到癌症：结直肠癌发生和治疗策略的整体观点。
Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463.
3
Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine.结直肠癌：精准医学的遗传基础与分子治疗。
Genes (Basel). 2024 Apr 25;15(5):538. doi: 10.3390/genes15050538.
4
Distinct Driver Pathway Enrichments and a High Prevalence of Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis.智利右半结肠癌中独特的驱动途径富集和高突变率：一项初步的比较分析。
Int J Mol Sci. 2024 Apr 25;25(9):4695. doi: 10.3390/ijms25094695.
5
The strain-dependent cytostatic activity of Lactococcus lactis on CRC cell lines is mediated through the release of arginine deiminase.乳球菌（Lactococcus lactis）的菌株依赖性细胞抑制活性通过释放精氨酸脱亚氨酶来介导对 CRC 细胞系的作用。
Microb Cell Fact. 2024 Mar 14;23(1):82. doi: 10.1186/s12934-024-02345-w.
6
Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?胰岛素受体底物4（IRS4）是一个参与多种癌基因激活的平台吗？
Cancers (Basel). 2023 Sep 20;15(18):4651. doi: 10.3390/cancers15184651.
7
Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations.马来西亚结直肠癌患者的全基因组测序揭示了特定的可靶向治疗的体细胞突变。
Front Mol Biosci. 2023 Feb 14;9:997747. doi: 10.3389/fmolb.2022.997747. eCollection 2022.
8
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.瑞士 512 例结直肠癌患者通过常规诊断中的靶向下一代测序分析的分子改变的流行率。
Pathobiology. 2023;90(3):166-175. doi: 10.1159/000526117. Epub 2022 Oct 6.
9
Differential Expression and Prognostic Correlation of Immune Related Factors Between Right and Left Side Colorectal Cancer.左右侧结直肠癌免疫相关因子的差异表达及预后相关性
Front Oncol. 2022 Jul 22;12:845765. doi: 10.3389/fonc.2022.845765. eCollection 2022.
10
The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.肿瘤微环境与免疫应答在结直肠癌发生发展及预后中的作用
Pathol Oncol Res. 2022 Jul 21;28:1610502. doi: 10.3389/pore.2022.1610502. eCollection 2022.
本文引用的文献
1
Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo.TGF-β 信号失活和 PTEN 缺失协同作用诱导体内结肠癌的发生。
Oncogene. 2014 Mar 20;33(12):1538-47. doi: 10.1038/onc.2013.102. Epub 2013 Apr 22.
2
WNT signalling pathways as therapeutic targets in cancer.WNT 信号通路作为癌症的治疗靶点。
Nat Rev Cancer. 2013 Jan;13(1):11-26. doi: 10.1038/nrc3419.
3
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.BRAF 突变型结肠癌对 BRAF 抑制的耐药性可以通过抑制 PI3K 或去甲基化剂来克服。
Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.
4
Selecting the best treatment for an individual patient.为个体患者选择最佳治疗方法。
Recent Results Cancer Res. 2012;196:307-18. doi: 10.1007/978-3-642-31629-6_20.
5
Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?将分子标志物与TNM分期系统相结合以改善II期和III期结肠癌的预后评估：我们准备好了吗？
J Natl Cancer Inst. 2012 Nov 7;104(21):1616-8. doi: 10.1093/jnci/djs441. Epub 2012 Oct 25.
6
TNM staging of colorectal carcinoma: issues and caveats.结直肠癌的 TNM 分期：问题与注意事项。
Semin Diagn Pathol. 2012 Aug;29(3):142-53. doi: 10.1053/j.semdp.2012.02.001.
7
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.磷脂酰肌醇 3-激酶信号通路的治疗靶向：结直肠癌治疗的新型靶向治疗和进展。
Therap Adv Gastroenterol. 2012 Sep;5(5):319-37. doi: 10.1177/1756283X12448456.
8
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.PIK3CA 突变在结直肠癌中的预后作用：队列研究和文献回顾。
Clin Cancer Res. 2012 Apr 15;18(8):2257-68. doi: 10.1158/1078-0432.CCR-11-2410. Epub 2012 Feb 22.
9
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?KRAS/BRAF 突变是否是结直肠癌强有力的预后和/或预测生物标志物？
Anticancer Agents Med Chem. 2012 Feb;12(2):163-71. doi: 10.2174/187152012799014968.
10
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.通过肿瘤基因组分析解析黑色素瘤中 RAF 抑制治疗抵抗。
J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.
Zotero 插件